v3.22.2.2
Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue $ 0 $ 0 $ 0 $ 0
Expenses:        
Research and development 6,578 7,718 21,312 25,777
General and administrative 3,448 3,641 10,887 15,322
Operating expenses 10,026 11,359 32,199 41,099
Other income/(expense):        
Interest income 254 22 387 72
Foreign exchange gain/(loss) (5) 4 (11) (3)
Total other income 249 26 376 69
Net loss (9,777) (11,333) (31,823) (41,030)
Other comprehensive income/(loss):        
Unrealized gain/(loss) on available-for-sale securities 20 0 (17) 0
Total comprehensive loss $ (9,757) $ (11,333) $ (31,840) $ (41,030)
Basic loss per common share (in dollars per share) $ (0.11) $ (0.13) $ (0.34) $ (0.46)
Weighted average number of common shares outstanding (in thousands) used in the calculation of basic loss per common share (in shares) 92,289 88,949 92,253 88,927
Diluted loss per common share (in dollars per share) $ (0.11) $ (0.13) $ (0.34) $ (0.46)
Weighted average number of common shares outstanding (in thousands) used in the calculation of diluted loss per common share (in shares) 92,289 88,949 92,253 88,927

Source